← SynDRA
MAVORIXAFOR
SynDRA canonical compound SYN0018464 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | CCR5 | CXCR4 |
|---|
| Mechanism of action | CC chemokine receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- CXCR4 ANTAGONIST
- C-X-C chemokine receptor type 4 antagonist
- CC chemokine receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CHRM2
- CYP2D6
- DRD2
- KCNH2
- ADRA2A
- MBD4
- TDG
- OPRM1
- OPRK1
- OGG1
- NTHL1
- NEIL2
- NEIL1
- MUTYH
- MPG
- HDAC6
- ADRA2C
- CYP3A4
- CYP2C19
- CXCR2
- CXCR1
- CHRNA7
- CCR4
- CCR2
- CCR1
- UNG
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
ATC classes
Cross-references
Synonyms
- XOLREMDI
- Xolremdi
- AMD-070
- Cxcr4 inhibitor x4p-001
- X4p001
- AMD-11070
- AMD070
- AMD11070
- X 4P-001
- X4P-001
- AMD 070
- S14-0353
- X4P 001
- AMD 11070
- 0G9LGB5O2W
- mavorixaforum
- RefChem:155995
- Mavorixafor [USAN]
- UNII-0G9LGB5O2W
- MFCD11977316
- Mavorixafor (USAN)
- C21H27N5
- Xolremdi (TN)
- Mavorixafor free base
- compound 2 [PMID: 20297846]
- AMD-070 (AMD11070)
- AMD-070; Mavorixafor
- MAVORIXAFOR [INN]
- A1D8L
- MAVORIXAFOR [WHO-DD]
- GTPL8580
- orb1296155
- SCHEMBL2511950
- SCHEMBL29379072
- SCHEMBL29701264
- CHEBI:138865
- GLXC-04447
- X4P-001-IO
- X4P-001-LD
Look up MAVORIXAFOR in the interactive SynDRA portal →